Back to Search
Start Over
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?
- Source :
- Clinical and Translational Science, Vol 14, Iss 2, Pp 502-508 (2021), Clinical and Translational Science
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Coronavirus disease 2019 (COVID-19) is often associated with interstitial pneumonia. However, there is insufficient knowledge on the presence of autoimmune serological markers in patients with COVID-19. We analyzed the presence and role of autoantibodies in patients with COVID-19-associated pneumonia. We prospectively studied 33 consecutive patients with COVID-19, 31 (94%) of whom had interstitial pneumonia, and 25 age-matched and sex-matched patients with fever and/or pneumonia with etiologies other than COVID-19 as the pathological control group. All patients were tested for the presence of antinuclear antibodies (ANAs), anti-antiphospholipid antibodies, and anti-cytoplasmic neutrophil antibodies (ANCAs). Clinical, biochemical, and radiological parameters were also collected. Fifteen of 33 patients (45%) tested positive for at least one autoantibody, including 11 who tested positive for ANAs (33%), 8 who tested positive for anti-cardiolipin antibodies (immunoglobulin (Ig)G and/or IgM; 24%), and 3 who tested positive for anti-β2-glycoprotein antibodies (IgG and/or IgM; 9%). ANCA reactivity was not detected in any patient. Patients that tested positive for auto-antibodies had a significantly more severe prognosis than other patients did: 6 of 15 patients (40%) with auto-antibodies died due to COVID-19 complications during hospitalization, whereas only 1 of 18 patients (5.5%) who did not have auto-antibodies died (P=0.03). Patients with poor prognosis (death due to COVID-19 complications) had a significantly higher respiratory rate at admission (23 breaths per minute vs. 17 breaths per minute; P=0.03) and a higher frequency of auto-antibodies (86% vs. 27%; P=0.008). In conclusion, auto-antibodies are frequently detected in patients with COVID-19 possibly reflecting a pathogenetic role of immune dysregulation. However, given the small number of patients, the association of auto-antibodies with an unfavorable prognosis requires further multicenter studies.
- Subjects :
- Adult
Male
030213 general clinical medicine
medicine.medical_specialty
Anti-nuclear antibody
Respiratory rate
autoantibodies
medicine.disease_cause
030226 pharmacology & pharmacy
Gastroenterology
Article
General Biochemistry, Genetics and Molecular Biology
Serology
coronavirus disease 2019
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
pneumonia
General Pharmacology, Toxicology and Pharmaceutics
Aged
Aged, 80 and over
biology
SARS-CoV-2
business.industry
lcsh:Public aspects of medicine
General Neuroscience
lcsh:RM1-950
Autoantibody
COVID-19
lcsh:RA1-1270
Articles
General Medicine
Middle Aged
Immunological Dysregulation
Immune dysregulation
medicine.disease
Autoantibodie
Pneumonia
lcsh:Therapeutics. Pharmacology
Immune System Diseases
biology.protein
Etiology
Female
prognosis
Antibody
business
Subjects
Details
- ISSN :
- 17528062 and 17528054
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Clinical and Translational Science
- Accession number :
- edsair.doi.dedup.....9e159de5ef38b0b42f3aa45c083038fb
- Full Text :
- https://doi.org/10.1111/cts.12908